A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Study Summary

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications. The aim of the study is to see how safe and effective aflibercept HD injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.

Conditions

Neovascular Age-Related Macular Degeneration Diabetic Macular Edema

Interventions / Drugs

Aflibercept 8 mg

View on ClinicalTrials.gov ↗

Sponsor

REGN

Regeneron Pharmaceuticals

Antibody Therapeutics

F34/100

Study Details

Enrollment1118 participants

Primary Completion—

Lead SponsorRegeneron Pharmaceuticals

Data Retrieved2026-04-11 02:55:54.866141+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.